113 related articles for article (PubMed ID: 3134000)
1. Intravitreal clearance of tissue plasminogen activator in the rabbit.
Jaffe GJ; Green GD; McKay BS; Hartz A; Williams GA
Arch Ophthalmol; 1988 Jul; 106(7):969-72. PubMed ID: 3134000
[TBL] [Abstract][Full Text] [Related]
2. Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery.
Murray TG; Jaffe GJ; McKay BS; Han DP; Burke JM; Abrams GW
Refract Corneal Surg; 1992; 8(1):44-8; discussion 48-53. PubMed ID: 1554639
[TBL] [Abstract][Full Text] [Related]
3. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.
Kamei M; Misono K; Lewis H
Am J Ophthalmol; 1999 Dec; 128(6):739-46. PubMed ID: 10612511
[TBL] [Abstract][Full Text] [Related]
4. Treatment of experimental intravitreal fibrin with tissue plasminogen activator.
Lambrou FH; Snyder RW; Williams GA; Lewandowski M
Am J Ophthalmol; 1987 Dec; 104(6):619-23. PubMed ID: 3120591
[TBL] [Abstract][Full Text] [Related]
5. Intraocular tissue plasminogen activator concentrations after subconjunctival delivery.
Lim JI; Maguire AM; John G; Mohler MA; Fiscella RG
Ophthalmology; 1993 Mar; 100(3):373-6. PubMed ID: 8460008
[TBL] [Abstract][Full Text] [Related]
6. Intraocular penetration of topical tissue plasminogen activator.
Lim JI; Fiscella R; Tessler H; Gagliano DA; Chaques-Alepuz V; Mohler MA
Arch Ophthalmol; 1991 May; 109(5):714-7. PubMed ID: 1902662
[TBL] [Abstract][Full Text] [Related]
7. Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
Min WK; Kim YB; Lee KM
Korean J Ophthalmol; 1990 Jun; 4(1):12-5. PubMed ID: 2120486
[TBL] [Abstract][Full Text] [Related]
8. Fibrin affinity and clearance of t-PA deletion and substitution analogues.
Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E
Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048
[TBL] [Abstract][Full Text] [Related]
9. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.
Ahn SJ; Ahn J; Park S; Kim H; Hwang DJ; Park JH; Park JY; Chung JY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):567-73. PubMed ID: 24398088
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic activity and localization of plasminogen activator in bovine vitreous body and aqueous humor.
Hayashi K; Nakashima Y; Sueishi K; Tanaka K
Jpn J Ophthalmol; 1989; 33(1):66-75. PubMed ID: 2499726
[TBL] [Abstract][Full Text] [Related]
11. Tissue plasminogen activator activity in human aqueous humor.
Smalley DM; Fitzgerald JE; Taylor DM; Cone RE; O'Rourke J
Invest Ophthalmol Vis Sci; 1994 Jan; 35(1):48-53. PubMed ID: 8300363
[TBL] [Abstract][Full Text] [Related]
12. Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.
Park SJ; Choi Y; Na YM; Hong HK; Park JY; Park KH; Chung JY; Woo SJ
Invest Ophthalmol Vis Sci; 2016 May; 57(6):2612-7. PubMed ID: 27258433
[TBL] [Abstract][Full Text] [Related]
13. [Tissue plasminogen activator and plasminogen activator inhibitor in aqueous humor].
Giedrojć J; Stankiewicz A; Walkowiak M; Galar M; Bielawiec M
Klin Oczna; 1996; 98(4):283-5. PubMed ID: 9463119
[TBL] [Abstract][Full Text] [Related]
14. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
[TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance.
Tripathi RC; Park JK; Tripathi BJ; Millard CB
Am J Ophthalmol; 1988 Dec; 106(6):719-22. PubMed ID: 3143267
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of D-dimer levels in aqueous humor of rabbit eyes with and without induced intraocular fibrin and fibrinolytic treatment.
Voelter K; Tappeiner C; Riond B; Nuss K; Bruetsch D; Pot SA
Vet Ophthalmol; 2020 Mar; 23(2):212-218. PubMed ID: 31441205
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
Zhao P; Wang W
Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
[TBL] [Abstract][Full Text] [Related]
19. Clearance of antitransferrin receptor immunotoxin from the rabbit eye.
Handa JT; Pearson A; Jaffe GJ
Curr Eye Res; 1996 Oct; 15(10):1039-44. PubMed ID: 8921243
[TBL] [Abstract][Full Text] [Related]
20. Clot uptake of labeled active and inhibited tissue plasminogen activator.
Lavie E; Bitton M; Shalev J; Weininger J; Abrashkin S; Varga E; Lubin E; Azoury R
Biochim Biophys Acta; 1989 Apr; 991(1):62-7. PubMed ID: 2496763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
